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Abstract
Background:  It has been shown that IAPs, in particular XIAP, survivin and c-IAP1, are
overexpressed in several malignancies. In the present study we investigate the expression of c-
IAP1, c-IAP2, XIAP and survivin and its isoforms in cervical cancer.
Methods: We used semiquantitative RT-PCR assays to analyze 41 cancer and 6 normal tissues.
The study included 8 stage I cases; 16 stage II; 17 stageIII; and a control group of 6 samples of normal
cervical squamous epithelial tissue.
Results: c-IAP2 and XIAP mRNA levels were similar among the samples, cervical tumors had
lower c-IAP1 mRNA levels. Unexpectedly, a clear positive association was found between low
levels of XIAP and disease relapse. A log-rank test showed a significant inverse association (p =
0.02) between XIAP expression and tumor aggressiveness, as indicated by disease relapse rates.
There were no statistically significant differences in the presence or expression levels of c-IAP1 and
c-IAP2 among any of the clinical variables studied. Survivin and its isoforms were undetectable in
normal cervical tissues, in contrast with the clear upregulation observed in cancer samples. We
found no association between survivin expression and age, clinical stage, histology or menopausal
state. Nevertheless, we found that adenocarcinoma tumors expressed higher levels of survivin 2B
and DeltaEx3 (p = 0.001 and p = 0.04 respectively, by Kruskal-Wallis). A multivariate Cox's partial
likelihood-based analysis showed that only FIGO stage was an independent predictor of outcome.
Conclusion: There are no differences in the expression of c-IAP2 and XIAP between normal vs.
cancer samples, but XIAP expression correlate in cervical cancer with relapse of this disease in the
patients. Otherwise, c-IAP1 was downregulated in the cervical cancer samples. The expression of
survivin was upregulated in the patients with cervical cancer. We have found that adenocarcinoma
presented higher levels of survivin isoforms 2B and DeltaEx3.
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Background
Life and death of cells must be balanced if tissue homeos-
tasis is to be maintained. The main (though not the only)
death mechanism by which mammalian cells maintain
homeostasis is apoptosis. Dysregulation of apoptosis
clearly contributes to the pathogenesis of various human
diseases including cancer. Defects in the apoptotic path-
way can eventually lead to expansion of a population of
neoplastic cells and affect the intrinsic ability to respond
to therapy.
Caspases, a group of cysteine proteases, are considered the
central executioners of apoptosis. The important role of
these proteins in cell death has generated intense research
in order to find both positive and negative regulators of
their activity. The physiological inhibitors of caspases are
a group of antiapoptotic proteins termed IAPs, which are
conserved across evolution, with homologues in both ver-
tebrate and invertebrate animal species.
So far, eight human IAPs have been identified. Among
these, XIAP (X-linked IAP) is the best-characterized. This
protein is a potent suppressor of apoptosis owing to its
ability to bind and inactivate caspases [1]. In addition to
their caspase-inactivating properties, c-IAP1 and c-IAP2
are parts of a signaling complex that is recruited to the
cytoplasmic domain of the type-2 Tumor Necrosis Factor
Receptor (TNFR2) [2]. XIAP, c-IAP1 and c-IAP2 are
thought to inhibit caspases 3, 7 and 9 directly [3]. Sur-
vivin, another member of the IAP family, is expressed dur-
ing embryonic development but is absent from terminally
differentiated adult tissues. This protein is prominently
expressed in transformed cell lines and in many human
tumors [4]. Survivin is structurally unique because unlike
other IAPs it contains only a single BIR repeat and lacks
the carboxyl-terminal RING domain. Its expression is reg-
ulated in a cell cycle-dependent manner with maximum
levels occurring during the G2/M phase [5]. In cell culture
systems, overexpression of survivin had been consistently
associated with inhibition of cell death initiated by either
the extrinsic or intrinsic apoptotic pathways [6], including
those mediated by p53 [7] and exposure to antineoplastic
agents [8]. In 1999, Mahotka et al. [9] described two novel
alternatively-processed survivin transcripts, designated
survivin-DEx3 (lacking exon 3) and survivin-2B (retaining
part of intron 2 as a cryptic exon). Survivin-Dex3 retains
its antiapoptotic function and survivin 2B shows a reduc-
tion of antiapoptotic potential compared to the type
form.
Resistant tumors pose a serious problem in the treatment
of cancer patients by antineoplastic agents. Although
there is some controversy, accumulating experimental evi-
dence supports the view that initial damage by chemo-
therapeutic agents converges into a common apoptotic
pathway. In this regard, upregulation of IAP family mem-
bers would certainly be advantageous for the tumors.
Indeed, as data regarding different tumors accumulate, a
widespread expression of IAPs, especially survivin, has
been revealed [10]. Additionally, roles have been pro-
posed for these proteins in cancer diagnosis and prognosis
and even as therapeutic targets [11]. Nevertheless, the
exact role of each IAP and their interplay in a particular
cancer type are as yet unclear.
In the present study, we analyzed the expression of XIAP,
survivin and its isoforms, c-IAP1 and c-IAP2 by means of
RT-PCR assays in cervical cancer samples.
Methods
Cell lines and tumor samples
Cervical cancer cell line (HeLa) was obtained from Amer-
ican Type Culture Collection and cultured as monolayer
in Dulbecco Modified Eagle Medium (DMEM) containing
10% (V/V) fetal bovine serum (GIBCO, Bethesda, MD,
USA) at 37°C in a humidified atmosphere of 5% (V/V)
CO2.
Cervical cancer samples were obtained from the Instituto
Nacional de Cancerología, México. Written consent was
obtained from patients before the samples were collected.
Tumors were classified according to the International
Gynecology and Obstetric Federation system (FIGO).
Ninety consecutive patients were recruited in the gyneco-
logic cancer clinic of the Institute. Due to failure of
patients to continue treatment and be subjected to clinical
follow-up, 31 were lost. In addition, 18 samples were
unsuitable for analysis, due to insufficient cancer tissue in
the histological control (see below). Thus, the study
included only 41 samples: 8 IB; 16 IIB; 17 IIIB; and a con-
trol group, 6 samples of normal cervical squamous epithe-
lial tissues. Histopathological grading was done according
to the FIGO (International Federation of Gynecology and
Obstetrics) classification system. The median follow-up
was 31.2 months, with a range of 19 to 57.7 months. Sam-
ples were assessed and only those which presented more
than 90% neoplastic cells were included. Forty-three per-
cent of the patients received radiotherapy, and the rest
received radiotherapy and chemotherapy.
Normal cervical tissue samples were used as controls and
were obtained after hysterectomy performed for benign
conditions such as myomatosis. All tissue samples were
used only after confirmation their malignancy or benig-
nity by a gynecological pathologist at the Surgical Pathol-
ogy Department of the Institute.
RNA isolation and RT-PCR
Extraction and RT-PCR analysis were performed as
described previously [12]. Briefly, total RNA was extractedBMC Cancer 2006, 6:45 http://www.biomedcentral.com/1471-2407/6/45
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Relative expression of IAP mRNAs, determined by semiquantitative RT-PCR in cervical cancer samples at different stages and  control normal cervical samples Figure 1
Relative expression of IAP mRNAs, determined by semiquantitative RT-PCR in cervical cancer samples at different stages and 
control normal cervical samples. a) c-IAP1 expression; b) c-IAP2 expression; c) XIAP expression; d) Survivin expression e) Sur-
vivin 2B expression f) Survivin DeltaEx3 expression. Procedures were performed as described in "Materials and Methods".BMC Cancer 2006, 6:45 http://www.biomedcentral.com/1471-2407/6/45
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from cell lines, tumoral and non-neoplastic tissue sam-
ples with Trizol reagent (Invitrogen) following the manu-
facturer's protocol. RNA purity was confirmed by the 260/
280 nm ratio and its integrity was established by agarose
gels. Total RNA (2 µg) was reverse-transcribed in a final 20
µl reaction volume using 15 U ThermoScript reverse tran-
scriptase, 2.5× RT Buffer and random hexamers (Thermo-
Script RT-PCR, Invitrogen). PCR reactions contained 0.25
µl amplitaq gold polymerase (Applied Biosystems,
ROCHE), 2.5 µl 10× reaction buffer, 0.5 µl dNTP mixture
(10 mM), 1 µl sense primer (10 µM), 1 µl anti-sense
primer (10 µM) and 1 µl cDNA in a 25 µl final volume.
Survivin primers were: sense 5' GCCATGAATTCATGGGT-
GCCCCGACGTTGC 3' and anti-sense 5' AGCTCTCTAGA-
GAGGCCTCAATCCATGGCA 3'. These primers are also
able to amplify the survivin isoforms 2B and DelatEx3.
XIAP primers were: sense 5' GCACGAGCAGGGTTTCTT-
TATACTGGTG 3' and antisense 5' CTTCTTCACAATACAT-
GGCAGGGTTCCTC 3'. c-IAP1 primers were: sense 5'
GAATACTCCCTGTGATTAATGGTGCCGTGG 3' and anti-
sense 5' TCTCTTGCTTGTAAAGACGTCTGTGTCTTC 3'. c-
IAP2 primers were: sense 5' GAATACTCCCTGTGATTAAT-
GCTGCCGTGG 3' and antisense 5' TCTCTTGCTTGTAAA-
GACGTCTGTGTCTTC 3'. GAPDH primers were: sense 5'
CCCCTTCATTGACCTCAACT 3' and antisense 5' TTGT-
CATGGATGACCTTGGC 3'. RT-PCR steps were 25° 10',
50°C 50' and 85°C 5'. To corroborate the specificity of
amplification, the PCR products were electrophored,
excised from the gel and sequenced.
The products were electrophoresed in 1% agarose gels
stained with ethidium bromide. A curve was generated for
each sample to verify that the amplification reactions pro-
ceeded logarithmically. The PCR products were normal-
ized to those obtained from GAPDH (mRNA)
amplification, used as internal reference gene and referred
to a HeLa cDNA standard for each gel. Gene expression
measurements were repeated at least twice. To corroborate
the specificity of amplification, the PCR products were
excised from the gel and sequenced.
Table 1: c-IAP1 expression in cervical cancer samples.
Variable No. patients (n = 41)* Median c-IAP1 expression AD p
FIGO stage
IB 8 (8) 141.23 40.14 0.14
IIB 16 (16) 178.02 39.80
IIIB 17 (17) 151.29 48.73
Histology of tumors
Squamous cell 34 (34) 160.14 45.80 0.09
Adenocarcinoma 5 (5) 198.01 20.93
Adenosquamous 2 (2) 135.45 22.40
Menopause
Pre-Menopause 10 (10) 148.69 34.33 0.61
Menopause 8 (8) 169.87 43.47
Post-Menopause 23 (23) 171.78 49.97
*Number of patients expressing c-IAP1 versus total patients in the respective group (in parenthesis). AD: absolute median deviation. Kruskall-
Wallis test used to test for differences.
Table 2: c-IAP2 expression in cervical cancer samples.
Variable No. patients (n = 41) Median c-IAP2 expression AD p
FIGO stage
IB 7 (8) 104.02 59.25 0.48
IIB 14 (16) 113.58 60.73
IIIB 17 (17) 125.55 28.42
Histology of tumors
Squamous cell 34 (34) 113.58 54.00 0.40
Adenocarcinoma 5 (5) 121.78 12.44
Adenosquamous 2 (2) 103.97 33.79
Menopause
Pre-Menopause 5 (10) 120.74 28.19 0.88
Menopause 5 (8) 102.65 43.70
Post-Menopause 23 (23) 121.78 58.16
*Number of patients expressing c-IAP2 versus total patients in the respective group (in parenthesis). AD: absolute median deviation. Kruskall-
Wallis test used to test for differences.BMC Cancer 2006, 6:45 http://www.biomedcentral.com/1471-2407/6/45
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Statistical analysis
To detect associations between pathological tumor
parameters and normalized IAP expression we used
Kruskal-Wallis test. Expression groups for XIAP and Sur-
vivin were defined using the 50th percentile of the cor-
rected semiquantitative RT-PCR data between each
variable and the categorized variable. Survival was evalu-
ated by Kaplan-Meier curves for patients with each varia-
ble and the curves were compared by a log rank test.
Statistical significance was inferred when the p value was
less than 0.05. To determine the influence of multiple var-
iables simultaneously, a multivariate Cox proportional
hazards model was applied to the clinical variables and
IAPs expression data. Wald's test was used to determine
statistical significance in the Cox models. The statistical
package SPSS 12.0 was used for these analyses.
Results and Discussion
In clear contrast to reports showing upregulation of sev-
eral IAPs in tumors such as lung and prostate, the IAP-2
and XIAP mRNA levels were similar among control and
cancer tissues (Fig. 1). There were no differences between
clinical variables, IAPs levels and therapy received. Inter-
estingly, cancer samples showed even lower c-IAP-1
mRNA levels than normal tissues (Median 205.51 ± 79.6
vs 161.22 ± 44.8, p= 0.04 by Kruskal-Wallis). There were
no statistically significant differences in the presence or
expression levels of c-IAP-1 and c-IAP-2 among any of the
clinical variables studied, including age, clinical stage, his-
tology, or menopausal state (Tables 1 and 2). Similarly,
no differences were found between XIAP expression and
stage, menopause or histology of the tumors (Table 3)
Nevertheless, a clear association was found between low
expression of XIAP and disease relapse (Fig. 2; log-rank p
= 0.02).
Table 3: XIAP expression in cervical cancer samples.
Variable No. patients (n = 41)* Median XIAP expression AD p
FIGO stage
IB 5 (8) 78.14 71.34 0.66
IIB 10 (16) 136.54 93.26
IIIB 11 (17) 93.96 78.65
Histology of tumors
Squamous cell 23 (34) 112.87 83.94 0.14
Adenocarcinoma 3 (5) 59.60 55.79
Adenosquamous 0 (2) 0 0
Menopause
Pre-Menopause 5 (10) 29.80 93.51 0.61
Menopause 5 (8) 138.25 77.86
Post-Menopause 16 (23) 103.52 81.19
*Number of patients expressing XIAP versus total patients in the respective group (in parenthesis). AD: absolute median deviation. Kruskall-Wallis 
test used to test for differences.
Table 4: Survivin expression in cervical cancer samples.
Variable No. patients (n = 41) Median Survivin expression AD p
FIGO stage
IB 5 (8) 236.74 107.26 0.34
IIB 10 (16) 187.67 88.25
IIIB 11 (17) 163.35 71.12
Histology of tumors
Squamous cell 23 (34) 186.10 91.47 0.18
Adenocarcinoma 3 (5) 162.37 54.84
Adenosquamous 0 (2) 164.04 93.16
Menopause
Pre-Menopause 5 (10) 165.07 75.41 0.88
Menopause 5 (8) 142.94 92.27
Post-Menopause 16 (23) 210.42 85.46
*Number of patients expressing Survivin versus total patients in the respective group (in parenthesis). AD: absolute median deviation. Kruskall-
Wallis test used to test for differences.BMC Cancer 2006, 6:45 http://www.biomedcentral.com/1471-2407/6/45
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While survivin is undetectable in normal, fully differenti-
ated tissues, high expression levels are observed in a broad
range of malignancies [4]. In the present report, survivin
and its isoforms were undetectable in normal cervical tis-
sues, in contrast to the clear upregulation observed in can-
cer samples (Fig. 1). High levels of survivin, which
correlated with clinical status, have been reported for sev-
eral malignancies [13]. We found no association between
survivin expression and clinical stage, histology or meno-
pausal state (Table 4). Similarly, no prognostic associa-
tion was found between survivin expression and disease
relapse or death (Fig. 3). Nevertheless, we found that even
when similar numbers of patients in the different clinical
stages expressed survivin isoforms, patients afflicted with
the clinically more aggressive adenocarcinoma tumors
expressed higher survivin 2B and DeltaEx3 levels (p =
0.001 and p = 0.04 respectively, by Kruskal-Wallis) (Table
5 and 6). When a multivariate Cox's partial likelihood-
based analysis was applied to the data, only FIGO stage
was an independent predictor of outcome (Table 7).
The inhibitors of apoptosis proteins (IAPs) are a family of
antiapoptotic proteins that share the BIR (Baculoviral IAP
Repeat) motif. These proteins bind and inhibit caspases 3,
7 and 9 and also modulate cell division, cell cycle progres-
sion and signal transduction pathways. In this regard, it
has been shown that tumor cells have high intrinsic levels
of apoptotic signaling and need proteins that inhibit
apoptosis to counterbalance this [14]. In addition, several
studies have demonstrated upregulation of certain IAPs in
response to chemotherapy, mediating cell resistance to
apoptosis [12]. For these reasons, several authors have
explored the possible use of IAPs as early diagnostic or
prognostic markers, and even as possible targets for malig-
nancy treatment. For example, IAPs such as survivin are
being investigated as diagnostic markers for the presence
of occult malignancy [10]. In addition, IAP overexpres-
sion is a poor prognostic marker for a variety of solid
tumors and hematological malignancies [15].
In the present study we found that in cervical cancer, most
of the IAPs analyzed were not overexpressed, with the
notable exception of survivin. These results are consistent
with the previous immunohistochemistry report of Liu et
al. [16], who found no differences in c-IAP-2 and XIAP
levels between normal and cancerous cervical samples.
Unexpectedly, we found a significant downregulation of
c-IAP1 in tumor samples. This change of expression could
be caused by a mechanism compensating for the
increased survivin level. It has been shown that c-IAP-1
interferes with the function of survivin in mitosis [17], so
it is not unreasonable to propose that concurrent expres-
Kaplan-Meier survival estimates in cervical cancer patients by  XIAP expression Figure 2
Kaplan-Meier survival estimates in cervical cancer patients by 
XIAP expression. Patients expressing low levels of XIAP ver-
sus high levels of XIAP, based on the 50th percentile, were 
plotted for relapse over the time shown (months). Statistical 
analysis was performed by a log rank test.
Table 5: Survivin 2B expression in cervical cancer samples.




IB 1 (8) 0.01 31.09 0.95
IIB 3 (16) 0.02 30.02
IIIB 3 (17) 0.05 38.15
Histology of tumors
Squamous cell 3 (34) 0.01 21.56 0.001
Adenocarcinoma 4 (5) 86 43.82
Adenosquamous 0 (2) 0 0
Menopause
Pre-Menopause 2 (10) 0.03 32.58 0.70
Menopause 2 (8) 0.02 40.27
Post-Menopause 3 (23) 0.1 31.94
*Number of patients expressing Survivin 2B versus total patients in the respective group (in parenthesis). AD: absolute median deviation. Kruskall-
Wallis test used to test for differences.BMC Cancer 2006, 6:45 http://www.biomedcentral.com/1471-2407/6/45
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sion of both proteins is not favored during carcinogenesis.
In addition, a previous report that c-IAP1 and 2 are upreg-
ulated in XIAP-deficient mice [18] supports the idea of a
compensatory mechanism. Alternatively, differences in
signal transduction cascades in cervical cancer could
account for the differences. One of the main IAP expres-
sion regulators is the pleiotropic transcription factor NF-
kappa B. This factor has emerged as a major culprit in a
variety of human cancers mainly because of its ability to
protect transformed cells from apoptosis. This protection
is, at least in part, afforded by the upregulation of IAPs
[19]. Heterogeneity in the components and transduction
signaling activation of this transcription factor has been
reported for specific breast cancer subgroups [20], so it is
plausible that in cervical cancer, differences in NF-kappa
B complexes could account for the lack of c-IAP1 and 2
overexpression.
It is noteworthy that, in contrast to most recent reports on
other cancer types, we found a positive role for XIAP as a
prognostic factor. A log-rank test showed a significant
inverse association (p = 0.02) between XIAP expression
and tumor aggressiveness as indicated by the rate of
relapse. This unexpected result could be due to differences
Kaplan-Meier survival estimates in cervical cancer patients by Survivin expression Figure 3
Kaplan-Meier survival estimates in cervical cancer patients by Survivin expression. Patients expressing low levels of Survivin 
versus high levels of Survivin, based on the 50th percentile, were plotted for A) Death and B) Relapse over the time shown 
(months). Statistical analysis was performed by a log rank test.
Table 6: Survivin DeltaEx3 expression in cervical cancer samples.




IB 0 (8) 0 0 0.59
IIB 2 (16) 0.09 24.51
IIIB 2 (17) 0.11 35.68
Histology of tumors
Squamous cell 2 (34) 0.01 16.99 0.04
Adenocarcinoma 2 (5) 0.22 60.12
Adenosquamous 0 (2) 0 0
Menopause
Pre-Menopause 2 (10) 0.14 48.94 0.33
Menopause 1 (8) 0.02 10.65
Post-Menopause 1 (23) 0.01 14.99
*Number of patients expressing Survivin DeltaEx3 versus total patients in the respective group (in parenthesis). AD: absolute median deviation. 
Kruskall-Wallis test used to test for differences.BMC Cancer 2006, 6:45 http://www.biomedcentral.com/1471-2407/6/45
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in mRNA and protein levels in particular tissue types.
Indeed, it has been shown that the translation of XIAP is
a highly regulated process [21]. As stated previously, IAPs
expression shows remarkable plasticity, so it is not
unlikely that differences in mRNA and protein levels
could have caused this result by means of a negative feed-
back on transcription. Further immunohistochemical
analyses are underway in our laboratory to elucidate this
matter.
Survivin is unique among IAPs in its ubiquitous expres-
sion during development and its absence from most nor-
mal adult tissues [4]. Its cell cycle-regulated expression at
mitosis and association with the mitotic apparatus are
related to the faithful segregation of sister chromatids and
timely separation of daughter cells. Survivin is re-
expressed in most cancers and associated with tumor
aggression and decreased patient survival rates [22], mak-
ing it an attractive diagnostic and therapeutic target. For
example, associations between high levels of survivin and
clinical status and/or prognosis have been reported in
colorectal cancer [23], among others. It has been shown
that survivin expression increases during cervical carcino-
genesis, following a gradient from low-grade squamous
intra-epithelial lesions to high-grade squamous epithelial
lesions and squamous tumors [24]. In the present study,
we found no association between survivin expression lev-
els and any clinical variable, as Lee et al. [25] reported on
the basis of immunohistochemical evidence. Similar
results were found in breast cancer [26], where survivin
expression did not correlate with tumor stage, histological
stage or nodal status; and in osteosarcoma and transi-
tional cell cancer [27]. Nevertheless, in the first two stud-
ies, a positive association was found between survivin
immunolocalization and prolonged survival. It seems
that not only the expression level but also the specific
location of the protein is important for the participation
of survivin in carcinogenesis. This pattern of sub-localiza-
tion and its relevance to cervical cancer warrant further
study.
Of clear interest was our finding that survivin isoforms
were expressed predominantly in adenocarcinomas.
Compared to squamous cell carcinoma, cervical adeno-
carcinoma has poorer prognosis, metastasizes earlier to
lymph nodes and is relatively resistant to radiotherapy
[28]. Higher levels of survivin 2B and deltaEx 3 were
found in adenocarcinoma samples, although there were
no prognostic implications for this upregulation. Our
results concur with recent reports about breast cancer
[29], where both isoforms were upregulated, and in brain
tumors [13], where survivin deltaEx 3 was also upregu-
lated. It is interesting to note that survivin 2B, which has
reduced antiapoptotic function [9], correlates negatively
with tumor stage, histological type and depth of tumor
invasion in gastric cancer [30]; although this is not univer-
sal, as stated previously. Additionally, it has been found
that an increased staining for survivin was found in cervi-
cal adenocarcinoma versus squamous cell carcinoma [31].
Since the antibodies used in this study do not discrimi-
nate between survivin isoforms, the results could be
reflecting the increase of total survivin levels, including all
Table 7: Analysis of maximum likelihood estimates under Cox's model.
Factor Hazard ratio (95% CI) p
(A) Univariate analysis of disease-free survival
FIGO stage 2.41 (1.10–5.00) 0.018
Age 1.00 (0.97–1.00) 0.075
Menopause 0.77 (0.46–1.31) 0.063
Histology 2.58 (1.24–5.41) 0.011
Survivin 0.99 (0.99–1.00) 0.295
Survivin2B 1.00 (0.99–1.01) 0.592
Survivin∆Ex3 1.00 (0.99–1.02) 0.187
XIAP 0.69 (0.59–0.94) 0.048
c-IAP1 0.99 (0.98–1.01) 0.334
c-IAP2 0.98 (0.96–1.00) 0.115
(B) Multivariate Cox model of disease-free survival
FIGO stage 3.13 (1.11–8.81) 0.031
Age 1.06 (0.98–1.13) 0.108
Menopause 0.29 (0.07–1.20) 0.089
Histology 1.77 (0.71–4.41) 0.071
Survivin 0.97 (0.99–1.00) 0.374
Survivin2B 1.00 (0.07–1.03) 0.743
Survivin∆Ex3 0.99 (0.07–1.02) 0.882
XIAP 0.79 (0.69–0.96) 0.516
c-IAP1 0.99 (0.97–1.01) 0.548
c-IAP2 0.99 (0.98–1.00) 0.486BMC Cancer 2006, 6:45 http://www.biomedcentral.com/1471-2407/6/45
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the known isoforms, as reported here. These data suggest
that careful consideration must be given to the relative
expression levels of the survivin splice isoforms in tumors.
We were not able to assess the prognostic significance of
these results because of our small sample size, but further
analyses are warranted by these preliminary findings.
Conclusion
It has been shown that IAPs, in particular XIAP, survivin
and c-IAP1, are overexpressed in several malignancies. In
the present report, we analyze the expression levels of
these proteins in cervical cancer by means of RT-PCR
assays. Two main conclusions derive from our results:
first, a clear positive association was found between low
levels of XIAP and disease relapse. The second, expected
from published results in other tumors, was the survivin
and its isoforms upregulation observed in cancer samples.
We found that adenocarcinoma tumors expressed higher
levels of the survivin 2B and DeltaEx3 isoforms. Unfortu-
nately, Cox multivariate analysis showed that only FIGO
stage is an independent prognostic factor in cervical can-
cer.
IAPs are attractive therapeutic targets, and efforts are
underway to develop antisense, vaccines and chemical
IAP inhibitors that may be useful for treating a variety of
malignancies [32-36]. Knowing the expression profiles of
IAPs in specific tumor types will undoubtedly help in
designing strategies to this end. Despite these potential
clinical applications, however, the challenge remains to
incorporate the findings into actual clinical practice.
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